BMC Nephrology

Table 2 ESA prescribing for hemodialysis patients by patients characteristics from September 2004 to August2009

From: Influence of safety warnings on ESA prescribing among dialysis patients using an interrupted time series

	Proportion prescribed	Average ESA dose/week
	ESA dose	Before and after FDA
	≥ 30,000 U/week	Black box warning *
	Overall	Base period		Followup
	%	Mean	Std_dev	Mean	Std_dev
All	20.8	19,486	23,742	18,191	21,581
Age (Year)
18–44	24.7	21,999	27,397	20,485	24,250
45–64	21.8	20,223	24,668	18,746	22,331
≥ 65	18.8	18,237	21,785	17,106	20,056
Race
White	19.5	18,427	22,794	17,229	21,008
Non-white	22.3	20,760	24,774	19,350	22,195
Gender
Male	20.3	18,956	23,937	17,733	21,620
Female	21.3	20,093	23,502	18,729	21,522
Diabetes Co-morbidity
Diabetic	20.7	19,541	23,223	18,154	21,094
Non-diabetic	20.8	19,443	24,141	18,221	21,964
Facility profit status
For-profit	22.3	20,943	24,241	19,514	21,927
Non-profit	13.9	13,481	20,496	12,185	18,797
Facility chain status
Chain 1 (FP)	24.5	23,509	26,658	20,680	22,316
Chain 2 (FP)	22.6	21,071	23,277	20,086	22,043
Medium chains	22.2	20,229	23,350	19,198	22,028
Small/nonchains	17.7	16,850	21,561	15,713	20,029
Hospital-based (NP)	9.9	10,364	19,605	7,700	16,809
Hematocrit value^#
< 30%	56.2	40,898	37,024	40,443	31,675
30 – < 36%	24.9	22,807	24,698	21,048	21,596
≥ 36%	13.6	16,383	18,621	13,041	14,971

Notes: FP For-profit, NP Nonprofit.
Base Period from September 2004 to February 2007. Followup from March 2007 to August 2009.
* P-value based on t-test comparison between base year and followup period within covariate levels was <.0001 for all variables.
# See Footnote from Table 1.

Back to article page

ISSN: 1471-2369

Contact us

Submission enquiries: bmcnephrology@biomedcentral.com
General enquiries: ORSupport@springernature.com